|drug897||Convalescent anti-SARS-CoV-2 MBT plasma Wiki||1.00|
|drug2247||None - NA Wiki||1.00|
|drug872||Control Group Wiki||1.00|
|D004932||Esophageal and Gastric Varices NIH||1.00|
|D005764||Gastroesophageal Reflux NIH||1.00|
There is one clinical trial.
The aim of this study is to evaluate patient and consultant experiences with phone consultations for endoscopy-related outpatient appointments during the COVID-19 outbreak.
Description: percentage of patients that did not answer phone calls (at least 3 calls) or with documented FTA for the retrospective group.Measure: Failed to attend patients Time: 2 months
Description: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020 - MSF and PAT-VC questionnaires). These are mostly Likert-scale response mode statements.Measure: Patient satisfaction with the phone consult Time: 2 months
Description: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020). These are mostly Likert-scale response mode statements.Measure: Consultant satisfaction with the phone consult Time: 2 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports